Rosuvastatin calcium in acute coronary syndromes

Bibliography

• WHO Fact sheet No 317. 2012. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html
   Google Scholar
• Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with Acute Coronary Syndromes in Europe and the Mediterranean basin: the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190-201
   PubMed Web of Science ®Google Scholar
• Mandelzweig L, Battler A, Boyko V, et al. for the Euro Heart Survey Investigators. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment and outcome of patients with ACS in Europe and the Mediterranean basin in 2004. Eur Heart J 2006;27(19):2285-93
   PubMed Web of Science ®Google Scholar
• Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010;31:2755-64
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054
   PubMed Web of Science ®Google Scholar
• Steg PhG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-619
   PubMedGoogle Scholar
• O'Gara PT, Kushner FG, Ascheim DD, et al. Task Force on Practice Guidelines A Report of the American College of Cardiology Foundation/American Heart Association 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Available from: http://circ.ahajournals.org/content/early/2012/12/17/CIR.0b013e3182742cf6.citation
   Google Scholar
• 2012 Writing Committee Members. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non -st-elevation myocardial infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2012;126:875-910
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Eur Heart Survey Programme. Eur Heart J 2001;22(7):554-72
   PubMed Web of Science ®Google Scholar
• Lopez LM. Managing hyperlipidemia: current and future roles of HMGCoA reductase inhibitors. Am J Health Syst Pharm 2002;59:1173-9
   PubMedGoogle Scholar
• Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 2008;9(12):2145-60
   PubMed Web of Science ®Google Scholar
• Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs 2002;11:125-41
   Web of Science ®Google Scholar
• Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMGCoA reductase. Science 2001;292:1160-4
   PubMed Web of Science ®Google Scholar
• McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003;26(Suppl III):III-32-I38
   Google Scholar
• Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000;151:41
   Google Scholar
• Warwick MJ, Dane AL, Raza A, Schneck DW. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 2000;151:39
   Google Scholar
• Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMGCoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG- CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J Clin Pharmacol 2000;40:1056
   Google Scholar
• Simonson SG, Martin PD, Mitchell P, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharacol 2003;58:669-75
   PubMed Web of Science ®Google Scholar
• Crestor Prescribing Information. AstraZeneca Pharmaceuticals, Wilmington, DE. 2012. Available from: http://www1.astrazeneca-us.com/pi/crestor.pdf [Last accessed 30 January 2013]
   Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94-9
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51-6
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-31
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92(4B):23K
   Web of Science ®Google Scholar
• McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 2005;96:60E-6E
   PubMed Web of Science ®Google Scholar
• Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91:3C-10C
   PubMed Web of Science ®Google Scholar
• Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomised, double-blind study. J Cardiovasc Risk 2001;8:383-90
   PubMedGoogle Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. JAMA 2007;297(12):1344-53
   PubMed Web of Science ®Google Scholar
• Underhill HR, Yuan C, Zhao XQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008;584(3):584. e1-8
   Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65
   PubMed Web of Science ®Google Scholar
• Takayama T, Hiro T, Yamagishi M, et al. for COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009;73(11):2110-17
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ballantayne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365(22):2078-87
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C- reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C- reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248-61
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE, et al. for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407
   PubMed Web of Science ®Google Scholar
• Marz W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011;6(6):1316
   PubMedGoogle Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181
   PubMed Web of Science ®Google Scholar
• Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287(23):3087
   PubMed Web of Science ®Google Scholar
• Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6
   PubMed Web of Science ®Google Scholar
• Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357:1063-8
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35(1):1
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 2001;1(6):411
   PubMedGoogle Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomised controlled trial. JAMA 2001;285:1711-18
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, Mcabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009;54:2290-5
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326-31
   PubMedGoogle Scholar
• Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS trial. J Am Coll Cardiol 2007;49:1272-8
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999;34(6):1696
   PubMedGoogle Scholar
• Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65(3):168
   PubMed Web of Science ®Google Scholar
• Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94(5):874
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5
   PubMed Web of Science ®Google Scholar
• Link A, Ayadhi T, Bohm M, et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006;27(24):2945-55
   PubMedGoogle Scholar
• Pitt B, Loscalzo J, Monyak J, et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol 2012;109(9):1239-46
   PubMed Web of Science ®Google Scholar
• Lablanchea JM, Leoneb A. Merkelyc B et al.; for the CENTAURUS investigators. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. Arch Cardiovasc Dis 2010;103:160-9
   PubMedGoogle Scholar
• Hall AS, Jackson BM, Farrin AJ, et al. on behalf of the SPACE ROCKET Trial Group. A randomised, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial. Eur J Cardiovasc Prev Rehabil 2009;16:712-21
   PubMedGoogle Scholar
• Bailey KM, Romaine SPR, Jackson BM, et al. on behalf of the SPACE ROCKET Trial Group. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction. The GEOSTAT-1 Study. Circ Cardiovasc Genet 2010;3:276-85
   PubMed Web of Science ®Google Scholar
• Otagiri K, Tsutsui H, Kumazaki S, et al. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome – analysis using integrated backscatter IVUS (ELAN Study). Circ J 2011;75(3):633-41
   PubMedGoogle Scholar
• Soeda T, Uemura S, Okayama S, et al. Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques. Evaluation using dual-source computed tomography. Circ J 2011;75(11):2621-7
   PubMedGoogle Scholar
• Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009;137(3):246-51
   PubMedGoogle Scholar
• Yun KH, Oh SK, Rhee SJ, et al. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2011;146(1):68-72
   PubMedGoogle Scholar
• Gao Y, Jia ZM, Sun YJ, et al. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome. Chin Med J (Engl) 2012;125(13):2250-4
   PubMedGoogle Scholar
• Alsheikh-Ali A, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005;111:3051-7
   PubMed Web of Science ®Google Scholar
• Grundy SM. The issue of statin safety: where do we stand [editorial]? Circulation 2005;111:3016-19
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang Y, An C, et al. Effects of rosuvastatin and atorvastatin on renal function-meta analysis. Circ J 2012;76:1259-66
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug–drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10:11-28
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012;28(3):371-8
   PubMed Web of Science ®Google Scholar
• Available from: http://www.mims.co.uk/Drugs/cardiovascular-system/hyperlipidaemia/atorvastatin/ [Last accessed 20 January 2013]
   Google Scholar
• Ara R, Pandor A, Stevens J, et al. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess (Winchester, England) 2009;13(34):1-74. 75-118
   PubMedGoogle Scholar
• Prinz V, Laufs U, Gertz K. Intravenous rosuvastatin for acute stroke treatment. An Animal Study. Stroke 2008;39:433-8
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900
   PubMed Web of Science ®Google Scholar